Achilles Therapeutics has sold certain technology assets to drug giant AstraZeneca for $12 million following a review of strategic alternatives by the clinical-stage biopharmaceutical company.
The clinical trial will assess CMND-100’s ability to reduce alcohol cravings and consumption among individuals with moderate to severe AUD. The study is designed to gather critical data supporting the ...